secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001701541-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026
--------------------------------------------------------------------------------

- Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.
- Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.
- Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.
- R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/0001701541-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/bdtx-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001701541-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer